Corcept Therapeutics Incorporated
CORTNASDAQHealthcare● Active
$74.88
+$2.26(+3.11%)
Market Cap$8.0B
P/E Ratio—
52W High$91
52W Low$28.66
Corcept Therapeutics Incorporated (CORT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CORT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.76B | $0.68B | $0.48B | $0.40B | $0.37B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Gross Profit | $0.75B | $0.66B | $0.48B | $0.40B | $0.36B |
| Gross Margin %(computed) | 98.30% | 98.39% | 98.66% | 98.66% | 98.56% |
| Operating Expenses | |||||
| R&D Expenses | $0.25B | $0.25B | $0.18B | $0.13B | $0.11B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.70B | $0.53B | $0.37B | $0.28B | $0.24B |
| Operating Income | $0.04B | $0.14B | $0.11B | $0.11B | $0.12B |
| Operating Margin %(computed) | 5.88% | 20.29% | 22.24% | 28.03% | 34.01% |
| Interest Income | $0.00B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.07B | $0.16B | $0.12B | $0.12B | $0.13B |
| Income Tax Expense | ($0.03B) | $0.02B | $0.02B | $0.01B | $0.01B |
| Net Income | $0.10B | $0.14B | $0.11B | $0.10B | $0.11B |
| Net Margin %(computed) | 13.09% | 20.70% | 22.00% | 25.24% | 30.74% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 |
| Wtd Avg Shares | 0.10B | 0.10B | 0.10B | 0.11B | 0.12B |
| EBITDA | $0.05B | $0.14B | $0.11B | $0.11B | $0.13B |
| EBITDA Margin %(computed) | 6.13% | 20.49% | 22.46% | 28.34% | 34.96% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Corcept Therapeutics Incorporated data
About Corcept Therapeutics Incorporated (CORT) Income Statement
Corcept Therapeutics Incorporated (CORT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CORT reported revenue of $0.76B, gross profit of $0.75B (gross margin 98.30%), and net income of $0.10B — a net profit margin of 13.09%.
Frequently asked questions
CORT · 4 questionsCorcept Therapeutics Incorporated (CORT) reported revenue of $0.76B for 2025, up 12.8% year-over-year.
CORT revenueCORT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08